Monopin (Lacidipine)

Lacidipine, the active ingredient in Monopin, is a dihydropyridine calcium channel blocker presented as an oral formulation for systemic use. It works by relaxing vascular smooth muscle, leading to vasodilation and a reduction in peripheral resistance, thereby lowering elevated blood pressure in adults diagnosed with hypertension.

GNH USA supplies Monopin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antihypertensive medication. The company adheres to stringent manufacturing standards and offers comprehensive logistics support for global distribution.

Lacidipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. - Essential hypertension: provides consistent blood pressure control in patients with primary hypertension. - Isolated systolic hypertension: effectively lowers elevated systolic pressure, particularly in older adults.

Lacidipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower limbs. - Dizziness: sensation of light‑headedness, especially when standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Angioedema: rapid swelling of face, lips, tongue or airway. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

When prescribing lacidipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check readings regularly after initiation and dose adjustments. - Liver function assessment: evaluate hepatic enzymes before starting therapy and periodically thereafter. - Concomitant antihypertensives: adjust doses of other blood‑pressure drugs to avoid excessive hypotension. - Elderly patients: start with the lowest effective dose and monitor for orthostatic effects. - Abrupt discontinuation: taper the medication gradually to prevent rebound hypertension. - Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels, raising risk of hypotension. - Grapefruit juice: can markedly elevate drug concentration and precipitate severe blood pressure drops. - Concurrent use with other calcium‑channel blockers: may cause additive vasodilatory effects and profound hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lacidipine effectiveness. - Beta‑blockers or ACE inhibitors: combined therapy may enhance antihypertensive response, requiring dose titration. - Diuretics: may increase risk of electrolyte imbalance and orthostatic hypotension. - NSAIDs: can attenuate antihypertensive effect of lacidipine.